Chemoradiotherapy for Locally Advanced Cervix Cancer Long UFT - - PowerPoint PPT Presentation

GOTIC-002 Metronomic Maintenance Chemotherapy after Chemoradiotherapy for Locally Advanced Cervix Cancer Long UFT Administration Trial (LUFT Trial)

 Co

Contin inuous ad admin inis istrat atio ion (w (wit ithout in interva val) l)

• f

f lo low d dose o

• f

f cytotoxic ic dr drug w wil ill l pr provid ide anti-an angio iogenet etic ic eff ffect, a , and d tumor do dorman ancy c y can an be be o

• bt

btai ained. d. Propo posed by d by Kerbe bel an and d Folk lkman an

Me Metr trono

• nomi

mic Che hemot mother herapy apy

UFT: : Mechani hanism sm of A f Action ion

O NH O H N O NH O N F O

UFT

＋

Uracli Tegafur （FT） GHB （γ-hydroxybutyric acid） GBL （γ-butyrolactone）

NH O H N O F

5-FU

O O O O OH OH HO

＋

HO COOH

Anti- angiogenetic effect Cytotoxic Effect

FdUMP FUTP TS inhibition F-RNA

Ra Randomi

• mized

zed Phase se III Tri Trial o l of Long g UF UFT T adminis inistra tration ion foll llowi wing ng curative ive radia iation ion therap apy y for lo locall lly advance anced d cervic ical al cancer er

GOT OTIC IC-002 002

Cervical ical Cancer ancer FIGO GO Ib2 Ib2-IVa IVa期 After er Chem emorad radiatio iation Regi gistratio stration Random andomizat izatio ion Stratifi atifica catio ion：Sta Stage ge（Ｉｂ２，ＩＩ ｖｓ ＩＩＩ，ＩＶa）、In Insti tituti tution

• n

Observation UFT

Trial ial Sche hema ma

300mg or 400mg / day bid 24 months

Target Accrual 530→350 Current 264

Primary Endpoint: PFS Secondary Endpoints: OS Toxicity Quality of Life（QOL） Cost Effectiveness

End ndpoints points